Search results for osteoporosis

Schedule Online - Alendronate for Osteoporosis

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?code=A190802

<< Drugs Affecting Bone Metabolism Online Pharmaceutical Schedule - October 2020 Alendronate for Osteoporosis Section B - Therapeutic Groups TG1 - Musculoskeletal System TG2 - Drugs Affecting Bone Metabolism Alendronate sodium Tab 70 mg Alendronate sodium with colecalciferol Tab 70 mg with colecalciferol 5,600 iu...

28d201_.DOC

https://www.pharmac.govt.nz/assets/ptac-minutes-2003-05.pdf

2003 Meeting of the Pharmacology and Therapeutics Advisory Committee Record of the 18 November 2002 meeting of the Osteoporosis Sub-committee The Committee reviewed the record of the 18 November 2002 Osteoporosis Sub-committee meeting as follows: Raloxifene The Committee agreed with the recommendations...

ptac-endocrinology-subcommittee-minutes-2018-05-17.pdf

https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2018-05-17.pdf

of the Endocrinology Subcommittee of PTAC teleconference held at PHARMAC on 17 May 2018 1 Denosumab for treatment of osteoporosis in men Application 1.1 The Subcommittee considered a paper from PHARMAC staff on denosumab for the treatment of osteoporosis in men. Recommendation 1.2 The Subcommittee...

RS1666.pdf

https://www.pharmac.govt.nz/2020/10/01/RS1666.pdf

(Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 Note: a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative...

Microsoft Word - content.doc

https://www.pharmac.govt.nz/assets/nzmj-2006-03-10-pharmac-responds-on-agents-to-prevent-osteoporotic-fractures.pdf

of osteoporotic fractures. We believe that the current access criteria for alendronate in the treatment of osteoporosis now has the potential to confer considerable population health gains, and that past criteria targeted alendronate so that other areas of health gain were not jeopardised. Discussions...

1

https://www.pharmac.govt.nz/assets/ptac-osteoporosis-subcommittee-minutes-2009-03.pdf

Osteoporosis Subcommittee of PTAC meeting held 31 March 2009 (minutes for web publishing) Osteoporosis Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008: Note that this document...

RS1665.pdf

https://www.pharmac.govt.nz/2020/10/01/RS1665.pdf

osteoporosis ❍ and The patient is female and postmenopausal ❍ or ❍ The patient is male or non-binary and History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or ❍equal to 2.5 standard deviations below the mean normal value...

Schedule Online - Alendronate sodium

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?osq=Alendronate%20sodium&code=C1908021037

<< Section B - Therapeutic Groups Online Pharmaceutical Schedule - October 2020 Alendronate for Osteoporosis Section B - Therapeutic Groups TG1 - Musculoskeletal System TG2 - Drugs Affecting Bone Metabolism TG3 - Alendronate for Osteoporosis Alendronate sodium        Tab 70 mg Fosamax 2022133 $2.44...

Record of the

https://www.pharmac.govt.nz/assets/ptac-osteoporosis-subcommittee-minutes-2009-08.pdf

Osteoporosis Subcommittee of PTAC meeting held 25 August 2009 (minutes for web publishing) Osteoporosis Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008. Note that this document...

SA1780.pdf

https://www.pharmac.govt.nz/2020/10/01/SA1780.pdf

and The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period ❑ INITIAL APPLICATION - Underlying cause - Osteoporosis Applications from any relevant practitioner. Approvals valid without further renewal unless notified. Prerequisites (tick boxes where...

Record of the

https://www.pharmac.govt.nz/assets/ptac-minutes-2010-05.pdf

Osteoporosis Treatments ............................................................................................... 6 6 Golimumab (Simponi) for second-line TNF-inhibitor treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis...

SA1779.pdf

https://www.pharmac.govt.nz/2020/10/01/SA1779.pdf

measurements (see Notes) or ❑ Patient has had a Special Authority approval for zoledronic acid (Underlying cause – Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 Note: a) BMD (including BMD used to derive T-Score...

No Slide Title

https://www.pharmac.govt.nz/assets/ss-rheumatology-update-4-osteoporosis-pdf.pdf

Current Osteoporosis Therapies and Their Long-term Use Ian Reid University of Auckland Treatment Approach Assess fracture risk Correct reversible risk factors Treat if risk justifies Follow-up Major osteoporotic fracture is hip fracture, clinically evident vertebral fracture, proximal humerus...

27 May 2003

https://www.pharmac.govt.nz/assets/notification-2012-11-05-decision-regarding-novartis-proposal.pdf

to support the clinical management of osteoporosis rather than ‘transported’ into other areas. The funding of risedronate was welcomed, however, some had concerns about it being open listed and there being consequent inappropriate use of risedronate. One responder was concerned that the proposal...

SA1777.pdf

https://www.pharmac.govt.nz/2020/10/01/SA1777.pdf

renewal unless notified. Prerequisites (tick boxes where appropriate) The patient has severe, established osteoporosis ❑ and The patient is female and postmenopausal ❑ or ❑ The patient is male or non-binary and History of one significant osteoporotic fracture demonstrated radiologically and documented...

Schedule Online - Alendronate sodium with colecalciferol

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?osq=Alendronate%20sodium%20with%20colecalciferol&code=C1908023868

<< Section B - Therapeutic Groups Online Pharmaceutical Schedule - October 2020 Alendronate for Osteoporosis Section B - Therapeutic Groups TG1 - Musculoskeletal System TG2 - Drugs Affecting Bone Metabolism TG3 - Alendronate for Osteoporosis Alendronate sodium with colecalciferol        Tab 70 mg with colecalciferol 5,600 iu Fosamax Plus 2337053 $1.51 per 4...

RS1663.pdf

https://www.pharmac.govt.nz/2020/10/01/RS1663.pdf

- Osteoporosis Re-assessment required after 3 doses Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by any specialist, or in accordance with a protocol or guideline that has been endorsed by the DHB Hospital. ❍ and History of one significant osteoporotic fracture demonstrated...

Schedule Online - Colecalciferol

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?osq=Colecalciferol&code=C0137101187

<< Section B - Therapeutic Groups Online Pharmaceutical Schedule - October 2020 Alendronate for Osteoporosis Section B - Therapeutic Groups TG1 - Musculoskeletal System TG2 - Drugs Affecting Bone Metabolism TG3 - Alendronate for Osteoporosis Alendronate sodium with colecalciferol        Tab 70 mg...

RS1723.pdf

https://www.pharmac.govt.nz/2020/10/01/RS1723.pdf

or ❍ Osteoporosis where there is significant risk of fracture or ❍ Severe acne following treatment with conventional corticosteroid therapy or ❍ History of severe psychiatric problems associated with corticosteroid treatment Form RS1723 October 2020 PRESCRIBER Name...

Rheumatology update

https://www.pharmac.govt.nz/seminars/seminar-resources/rheumatology-update-2/

Rheumatology update Presentations Rheumatoid arthritis  - Prof. Andrew Harrison Psoriatic arthropathy - Dr Will Taylor (parts 1, 2) Gout - Dr Guy Taylor (parts 1, 2) Osteoporosis - Prof. Ian Reid (parts 1, 2) Telemedicine in rheumatology care for rural practice - Frances Kasmi 1. Rheumatoid...

ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf

https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf

should no longer be used to treat osteoporosis due to an unfavourable risk: benefit profile. In particular, the PRAC highlighted the cardiovascular risks (including heart attacks and blood clots) as well as serious skin reactions, disturbances in consciousness, seizures, liver inflammation and reduced...

Funding options that PHARMAC had before it during 2009/10 that were not funded (implemented) during that year

https://www.pharmac.govt.nz/assets/annual-report-2009-2010-funding-options-not-taken.pdf

cooler 10mg,15mg, 20mg Phenylketonuria (PKU) <100 Protein drink MSUD Maple Syrup Urine Disease <100 Quetiapine extended-release tablets Schizophrenia and bipolar disorder 1,000-10,000 Raloxifene Osteoporosis - first line 10,000-50,000 Raloxifene Osteoporosis in patients intolerant to bisphosphonates...

Interacting in a Māori Context

https://www.pharmac.govt.nz/assets/ss-medicines-3a-medicines-in-context-leanne-te-karu.pdf

)] Antiulcerants [Peptic ulcer disease] Diabetes Rx etc [Diabetes mellitus] Rx for osteoporosis [Osteoporosis] Rx used for cancers [cancers] Rx for asthma &/or CORD [asthma/CORD] other neurol Rx [other neurological] other alimentary Rx [other GI/hepatic] Antiepilepsy Drugs [Epilepsy] ADHD Rx [Childhood conduct...

Microsoft Word - 2vg301_.DOC

https://www.pharmac.govt.nz/assets/ptac-minutes-2005-11.pdf

considered an application by Eli Lilly for the listing of raloxifene on the Pharmaceutical Schedule under the same Special Authority criteria as applied to alendronate (without the indication of glucocorticosteroid-induced osteoporosis). The Committee noted that the Osteoporosis Sub-committee had...

Schedule Online - Drugs Affecting Bone Metabolism

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?code=A1908

<< Musculoskeletal System Online Pharmaceutical Schedule - October 2020 Drugs Affecting Bone Metabolism Section B - Therapeutic Groups TG1 - Musculoskeletal System Alendronate for Osteoporosis Alendronate sodium; Alendronate sodium with colecalciferol Other Treatments Denosumab; Pamidronate disodium; Raloxifene hydrochloride; Risedronate sodium; Teriparatide; Zoledronic acid...

ptac-endocrinology-subcommittee-minutes-2016-06.pdf

https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2016-06.pdf

valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient is a postmenopausal woman with severe, established osteoporosis; and 2 Any of the following: 2.1 History of one significant osteoporotic fracture demonstrated...

SA1886.pdf

https://www.pharmac.govt.nz/2020/10/01/SA1886.pdf

or ❑ Osteoporosis where there is significant risk of fracture or ❑ Severe acne following treatment with conventional corticosteroid therapy or ❑ History of severe psychiatric problems associated with corticosteroid treatment Ministry of Health Phone 0800 243 666 APPLICANT (stamp or sticker...

Schedule Online - Musculoskeletal System

https://www.pharmac.govt.nz/wwwtrs/ScheduleOnline.php?code=A19

and Muscular Pain Topical Products for Joint and Muscular Pain Antirheumatoid Agents Antirheumatoid Agents Drugs Affecting Bone Metabolism Alendronate for Osteoporosis; Other Treatments Hyperuricaemia and Antigout Hyperuricaemia and Antigout Muscle Relaxants Muscle Relaxants...

SA1139.pdf

https://www.pharmac.govt.nz/2020/10/01/SA1139.pdf

severe, established osteoporosis ❑ and The patient has a documented T-score less than or equal to -3.0 (see Notes) ❑ and The patient has had two or more fractures due to minimal trauma ❑ and ❑ The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy...

RS1143.pdf

https://www.pharmac.govt.nz/2020/10/01/RS1143.pdf

: ............................................................................................. Teriparatide NHI: ............................................................................................... INITIATION Re-assessment required after 18 months Prerequisites (tick boxes where appropriate) The patient has severe, established osteoporosis...